Results 171 to 180 of about 2,327,860 (219)

Incidence of Seizure in Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Systematic Review and Meta-Analysis

International Journal of Stroke, 2017
Background Recombinant tissue plasminogen activator is the only FDA-approved thrombolytic agent for acute stroke treatment. However, there are concerns that recombinant tissue plasminogen activator may increase the risk of seizures (including early and ...
Alain Lekoubou, Andre P Kengne
exaly   +2 more sources

Recombinant Tissue Plasminogen Activator for Acute Ischaemic Stroke: An Updated Systematic Review and Meta-Analysis [PDF]

Lancet, The, 2012
Recombinant tissue plasminogen activator (rt-PA, alteplase) improved functional outcome in patients treated soon after acute ischaemic stroke in randomised trials, but licensing is restrictive and use varies widely.
Peter Sandercock, Richard I Lindley, Eivind Berge   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Dialysis Catheters and Recombinant Tissue Plasminogen Activator

New England Journal of Medicine, 2011
exaly   +3 more sources

Physical characterization of recombinant tissue plasminogen activator

Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1993
Electron microscopic and physical-chemical properties of one- and two-chain tissue plasminogen activator (t-PA) were studied. The molecular weight of one-chain t-PA obtained by both sedimentation equilibrium and SDS-PAGE was estimated to be about 65,000, while both chains in the reduced two-chain form were in the range of 35,000-40,000.
S S, Margossian, H S, Slayter, E, Kaczmarek, J, McDonagh   +3 more
openaire   +2 more sources

Evaluation of recombinant tissue plasminogen activator in embolic stroke

Neurosurgery, 1989
Abstract In an effort to determine the value of tissue-type plasminogen activator (TPA) in the treatment of embolic stroke, 17 rabbits were subjected to a model of embolic stroke in which 2-hour-old, tin-impregnated, autologous clots were embolized to the bifurcation of the internal carotid artery at the circle of Willis via retrograde ...
B B, Chehrazi, J A, Seibert, P, Kissel, L, Hein, J M, Brock   +4 more
openaire   +2 more sources

Recombinant tissue-type plasminogen activators: "time matters"

Drugs of Today, 2011
Although acute ST elevation myocardial infarction (STEM!) was described nearly a century ago, it remains a major health problem not only in the U.S. but also worldwide with more than three million people suffering STEMI every year. Primary percutaneous coronary intervention (PPCI) is now the treatment of choice for the management of patients with STEMI.
Vijayalakshmi Kunadian, C. M. Gibson
openaire   +2 more sources

Clearance of a novel recombinant tissue plasminogen activator in rabbits

Thrombosis Research, 1988
The pharmacokinetic properties of hPA(B), characterized by the insertion of a urokinase kringle coding region before the double kringle of tPA plus the complete tPA coding region, were investigated and compared to those of melanoma tPA (mtPA). Mean peak plasma concentrations at the end of infusion were 4.7 micrograms/ml for hPA(B) and 4.6 micrograms/ml
K P, Fu, S, Lee, N, Hetzel, R, Fenichel, H W, Hum, J, Speth, N, Kalyan, P P, Hung   +7 more
openaire   +2 more sources

Recombinant Tissue Plasminogen Activator: A Brief Review

Pharmaceutical Research, 1987
Thrombolytic therapy has received renewed attention with the demonstration that early treatment of acute myocardial infarction with plasminogen activators can reduce mortality. Tissue plasminogen activator (t-PA) is a protein with attributes that may allow for greater efficacy and safety.
openaire   +2 more sources

Retinal Toxicity of Recombinant Tissue Plasminogen Activator in the Rabbit

Archives of Ophthalmology, 1990
We studied the dose-dependent retinal toxicity of the available commercial preparation of human recombinant tissue plasminogen activator in the normal rabbit eye. Tissue plasminogen activator was injected into the midvitreous cavity of albino rabbits in doses (per 100 microL) of 25, 50, 75, and 100 micrograms.
M W, Johnson, K R, Olsen, E, Hernandez, W D, Irvine, R N, Johnson   +4 more
openaire   +2 more sources

Nonproteolytic Neuroprotection by Human Recombinant Tissue Plasminogen Activator

Science, 1999
Human recombinant tissue plasminogen activator (tPA) may benefit ischemic stroke patients by dissolving clots. However, independent of thrombolysis, tPA may also have deleterious effects on neurons by promoting excitotoxicity. Zinc neurotoxicity has been shown to be an additional key mechanism in brain injuries. Hence, if tPA affects zinc neurotoxicity,
Y H, Kim, J H, Park, S H, Hong, J Y, Koh
openaire   +2 more sources